# Monoclonal Antibody Therapy in Treating Patients With Brain Metastases

> **NCT00002751** · PHASE1,PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 6 (estimated)

## Conditions studied

- Metastatic Cancer

## Interventions

- **BIOLOGICAL:** monoclonal antibody Me1-14 F(ab')2

## Key facts

- **NCT ID:** NCT00002751
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1989-07
- **Primary completion:** —
- **Final completion:** 2004-05
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002751, "Monoclonal Antibody Therapy in Treating Patients With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*